Replies to post #105280 on Biotech Values

[DewDiligence]

…what are your thoughts if any regarding PYMX's Lovenox/heparin reversal agent?

I think the two markets—Lovenox reversal and UFH reversal—have to be considered separately.

Lovenox reversal is an impressive scientific achievement; however, I’m not sure the business impetus for such a product is strong because Lovenox, unlike UFH, is not often used in medical settings where reversal is likely to be needed.

UFH reversal is potentially a big market, so the question here is: To what extent does the superior safety of PMX-60056 warrant a premium price relative to protamine (which is dirt cheap)? Unless PYMX is able to make a convincing economic case that hospitals will save money in the long run by using PMX-60056 instead of protamine, I’m not sure hospitals will readily accept the purely medical justification. Moreover, the squeezing of hospitals’ operating margins under ObamaCare might impede the commercial uptake of PMX-60056. Regards, Dew

p.s. Welcome to the board!